Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
On Jan. 22, 2019, the U.S. Supreme Court issued a unanimous opinion, authored by Justice Thomas, in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. __ (2019) (http://bit.ly/2Eixoxq), holding that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art under 35 U.S.C. §102(a).
In early 2000, Helsinn Healthcare S. A. (Helsinn), a Swiss pharmaceutical company, submitted protocols to the Food and Drug Administration (FDA) for clinical trials of 0.25mg and 0.75 mg doses of palonosetron a drug for treating chemotherapy-induced nausea. Subsequently, Helsinn entered into a license agreement, and a supply and purchase agreement for palonosetron with MGI Pharma, Inc. (MGI).
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
This article explores legal developments over the past year that may impact compliance officer personal liability.